Protect Pharmaceutical Corporation

Protect Pharmaceutical Corporation

PRTT
Protect Pharmaceutical CorporationUS flagOther OTC
0.06
USD
- -
- -
3.39MMarket Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.06
-172.65
-18.14
-12.44
-0.54
8.48
-1.44
-0.04
-0.11
-0.01
Free Cash Flow per Basic Share
- -
- -
-11.07
-0.48
- -
- -
-0.04
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-18.3
-186.31
-190.87
-200.26
-205.79
-161.24
-21.13
-8.45
-8.56
-8.56
Tangible Book Value per Share
-0.16
-11.28
-0.66
-12.95
-13.35
-2.24
-0.23
-0.02
-0.13
-0.14
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-7
-1
-1
- -
- -
-1
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
-1
-1
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
-1
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-5.12
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
1
1
1

Working Capital

FRC

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
83.17%
588.63%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
-449.53%
193.98%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
-0.01
-0.01
- -
-0.04
2017
-0.01
-0.09
- -
- -
-0.11
2018
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Alan Crooks
Full Time Employees
3
Sector
Industrials
Industry
Conglomerates
Address
4876 Cecile Avenue Las Vegas NV United States of America 89115
IPO Date
Aug 1, 2006
Business
Protect Pharmaceutical Corporation Protect Pharmaceutical Corporation (OTC: PRTT), founded in 1987 and headquartered in Las Vegas, Nevada, operates primarily in the integrated freight and logistics sector, providing international road, seaway, airline freight, and intermodal transportation services; it also maintains involvement in crop farming and agricultural businesses through ownership of the Can Noguera property in Spain's Selva Girona region, encompassing 60 hectares of arable land, 390 hectares of forests, six wells, and built structures; additionally, the company has pursued agropharmacy products for soil revitalization and plant microflora normalization, alongside historical interests in pharmaceuticals, drug delivery systems, and software development in areas such as blockchain and NFTs. The company serves business-to-business and business-to-consumer markets with a focus on transportation needs, supply chain solutions, and agricultural enhancements, operating across North America, Europe including Spain and Turkey, and Asia. In recent developments, Protect Pharmaceutical finalized a merger with KARINCA Logistics in August 2024 to expand its network, routes, and sales in Europe and Asia without common share dilution via issuance of 1 million preferred shares, though by September 2024 announced the merger would not proceed; leadership changes included appointment of Ozgur Ozcan as CEO and George Athanasiadis as director in August 2024, followed by Athanasiadis's resignation, with plans to complete PCAOB audit, file Form 10 for SEC reporting resumption, pursue exchange uplisting, and consider a name change to reflect logistics focus.

Company News

APIChat
  • Protect Pharmaceutical Corp. Announces that KARINCA Logistics Merger Will Not Proceed

  • Protect Pharmaceutical Corp. (PRTT) Announces New CEO and New Director; Moves to Finalize the Karinca Logistics Merger

  • Protect Pharmaceutical Corp. Issues Corporate Update

  • Protect Pharmaceutical Corp.'s President, Ali Yildiz, Issues a Letter to Shareholders

  • Ali Yildiz, President of Protect Pharmaceutical Corp., Issues Letter to Shareholders

  • Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp.

  • Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp.

  • Protect Pharmaceutical Corp. CEO Provides Shareholder Update

  • Protect Pharmaceutical Corp. Acquires Bosfor Export

  • Protect Pharmaceutical Corp. CEO Provides Shareholder Update

  • Protect Pharmaceutical Corp. Announces Appointment Of